Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US.

Conclusion: The majority of women diagnosed with bone metastasis from breast cancer initiate a BMA within 1 year of diagnosis, but a large proportion, particularly among the elderly, do not use these therapies.
PMID: 30288124 [PubMed]

Source: Clinical Breast Cancer - October 6, 2018 Category: Cancer & Oncology Authors: McGrath LJ, Overman RA, Reams D, Cetin K, Liede A, Narod SA, Brookhart MA, Hernandez RK Tags: Clin Epidemiol Source Type: research